{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":15,"n_cols":5,"rows_kept":15,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[3,2,3,3],[4,2,4,3],[5,2,5,3],[6,2,6,3],[9,2,9,3],[10,2,10,3],[12,2,12,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910647231703321"]
[null,null,"Titolo",null,"Frontiers of Targeted Therapy and Predictors of Treatment Response in Systemic Sclerosis / / by Michal Tomcik editor"]
[null,null,"Pubbl/distr/stampa",null,"[Place of publication not identified] : , : MDPI - Multidisciplinary Digital Publishing Institute, , 2023"]
[null,null,"ISBN",null,"3-0365-6122-6"]
[null,null,"Descrizione fisica",null,"1 online resource (218 pages)"]
[null,null,"Disciplina",null,"616.544"]
[null,null,"Soggetti",null,"Systemic scleroderma"]
[{"$nulls":4},"Scleroderma, Systemic - diagnosis"]
[{"$nulls":4},"Scleroderma, Systemic - therapy"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,"Nota di contenuto",null,"About the Editor vii -- Preface to \"Frontiers of Targeted Therapy and Predictors of Treatment Response in Systemic Sclerosis \" ix -- Frontiers of Targeted Therapy and Predictors of Treatment Response in Systemic Sclerosis 1 -- Therapeutic Options for Systemic Sclerosis: Current and Future Perspectives in Tackling -- Immune-Mediated Fibrosis 5 -- Targeting Systemic Sclerosis from Pathogenic Mechanisms to Clinical Manifestations: Why -- IL-6-37 -- Novel Concepts in Systemic Sclerosis Pathogenesis: Role for miRNAs 55 -- MiRNAs in Systemic Sclerosis Patients with Pulmonary Arterial Hypertension: Markers and Effectors 73 Inhibition of Hsp90 Counteracts the Established Experimental Dermal Fibrosis Induced by Bleomycin 91 -- Plasma Metabolomic Profiling Reveals Four Possibly Disrupted Mechanisms in Systemic Sclerosis 109 -- Autoantibodies as Biomarker and Therapeutic Target in Systemic Sclerosis 125 Emerging Evidence and Treatment Perspectives from Randomized Clinical Trials in Systemic Sclerosis: Focus on Interstitial Lung Disease 155 -- Clinical Predictors of Lung-Function Decline in Systemic-Sclerosis-Associated Interstitial Lung -- Disease Patients with Normal Spirometry 173 -- Treatment and Systemic Sclerosis Interstitial Lung Disease Outcome: The Overweight Paradox 185 -- Bisphosphonates for the Treatment of Calcinosis Cutis-A Retrospective Single-Center Study 199."]
[null,null,null,"Sommario/riassunto","Systemic sclerosis (scleroderma) is an incurable connective tissue disease with an unclear etiology characterized by vasculopathy, dysregulation of the immune response, and progressive tissue fibrosis "]
[{"$nulls":4},"affecting the skin, lungs, digestive tract, heart, and kidneys. The collection of six original research manuscripts and five review articles included in this book highlights the most recent advances in this field and provides further elucidation of the pathogenesis, natural disease course, and treatment of this challenging disease."]